WILLIAM WONG to Antiviral Agents
This is a "connection" page, showing publications WILLIAM WONG has written about Antiviral Agents.
Connection Strength
3.749
-
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology. 2024 08 01; 80(2):440-450.
Score: 0.580
-
Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
Score: 0.580
-
Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver Int. 2023 04; 43(4):805-818.
Score: 0.538
-
A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value Health. 2020 01; 23(1):127-137.
Score: 0.431
-
Antiviral treatment for treatment-na?ve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019 08 19; 8(1):207.
Score: 0.423
-
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol. 2013 Mar; 27(3):137-47.
Score: 0.270
-
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021 Jan-Mar; 9(1):E167-E174.
Score: 0.118
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
Score: 0.115
-
Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat. 2020 12; 27(12):1419-1429.
Score: 0.114
-
The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver Int. 2020 06; 40(6):1282-1291.
Score: 0.111
-
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2020 01; 40(1):51-59.
Score: 0.106
-
Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
Score: 0.101
-
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat. 2015 Jun; 151(3):639-52.
Score: 0.079
-
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Feb 17; 187(3):E110-E121.
Score: 0.077
-
Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada. Viruses. 2024 07 31; 16(8).
Score: 0.037
-
Engagement with the HCV care cascade among high-risk groups: A population-based study. Hepatol Commun. 2023 09 01; 7(9).
Score: 0.035
-
Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023 04 11; 195(14):E499-E512.
Score: 0.034